A Double-blind, Placebo-Controlled, Fixed-Dose Study of F2695 SR in Patients With Major Depressive Disorder
| City: |
|
Wichita |
| State: |
|
Kansas |
| Zip Code: |
|
67206 |
| Conditions: |
|
Major Depressive Disorder |
| Purpose: |
|
The purpose of this study is to evaluate the efficacy, safety, and tolerability of F2695 SR
fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Men and women, 18-65 years old
- Currently meet the DSM-IV-TR criteria for Major Depressive Disorder
- The patient's current depressive episode must be at least 8 weeks in duration
Exclusion Criteria:
- Women who are pregnant, women who will be breastfeeding during the study, and women
with childbearing potential who are not practicing a reliable method of birth control
- Patients with a history of meeting DSM-IV-TR criteria for:
- any manic or hypomanic episode
- schizophrenia or any other psychotic disorder
- obsessive-compulsive disorder
- Patients who are considered a suicide risk
|
| NCT ID: |
|
NCT00969709 |
| Primary Contact: |
|
Study Director
Carl Gommoll, MS
Forest Research Institute, a subsidiary of Forest Laboratories Inc.
Sandra Beaird, PhD
Phone: 1-800-678-1605 ext. 66297
Email: info@forestpharm.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Wichita, Kansas 67206
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|